Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients

Standard

Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. / Steinacker, Petra; Feneberg, Emily; Weishaupt, Jochen; Brettschneider, Johannes; Tumani, Hayrettin; Andersen, Peter M; von Arnim, Christine A F; Böhm, Sarah; Kassubek, Jan; Kubisch, Christian; Lulé, Dorothée; Müller, Hans-Peter; Muche, Rainer; Pinkhardt, Elmar; Oeckl, Patrick; Rosenbohm, Angela; Anderl-Straub, Sarah; Volk, Alexander E; Weydt, Patrick; Ludolph, Albert C; Otto, Markus.

In: J NEUROL NEUROSUR PS, Vol. 87, No. 1, 01.2016, p. 12-20.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

Steinacker, P, Feneberg, E, Weishaupt, J, Brettschneider, J, Tumani, H, Andersen, PM, von Arnim, CAF, Böhm, S, Kassubek, J, Kubisch, C, Lulé, D, Müller, H-P, Muche, R, Pinkhardt, E, Oeckl, P, Rosenbohm, A, Anderl-Straub, S, Volk, AE, Weydt, P, Ludolph, AC & Otto, M 2016, 'Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients', J NEUROL NEUROSUR PS, vol. 87, no. 1, pp. 12-20. https://doi.org/10.1136/jnnp-2015-311387

APA

Steinacker, P., Feneberg, E., Weishaupt, J., Brettschneider, J., Tumani, H., Andersen, P. M., von Arnim, C. A. F., Böhm, S., Kassubek, J., Kubisch, C., Lulé, D., Müller, H-P., Muche, R., Pinkhardt, E., Oeckl, P., Rosenbohm, A., Anderl-Straub, S., Volk, A. E., Weydt, P., ... Otto, M. (2016). Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J NEUROL NEUROSUR PS, 87(1), 12-20. https://doi.org/10.1136/jnnp-2015-311387

Vancouver

Steinacker P, Feneberg E, Weishaupt J, Brettschneider J, Tumani H, Andersen PM et al. Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J NEUROL NEUROSUR PS. 2016 Jan;87(1):12-20. https://doi.org/10.1136/jnnp-2015-311387

Bibtex

@article{4e0c7d354bc54a61b51e99b5c7c41d25,
title = "Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients",
abstract = "OBJECTIVES: Biomarkers for the diagnosis of motoneuron diseases (MND) are urgently needed to improve the diagnostic pathway, patient stratification and monitoring. The aim of this study was to validate candidate markers for MND in cerebrospinal fluid (CSF) and specify cut-offs based on large patient cohorts by especially considering patients who were seen under the initial differential diagnosis (MND mimics).METHODS: In a prospective study, we investigated CSF of 455 patients for neurofilament light chain (NfL), phosphorylated heavy chain (pNfH), tau protein (Tau) and phospho-tau protein (pTau). Analysed cohorts included patients with apparently sporadic and familial amyotrophic lateral sclerosis (ALS) and primary lateral sclerosis (PLS) (MND, n=253), MND mimics (n=85) and neurological control groups. Cut-off values were specified, and diagnostic performance and correlation with progression were analysed.RESULTS: Nfs were significantly higher in the MND group compared to the control groups, whereas Tau and pTau did not differ. At a cut-off level of 2200 pg/mL for NfL, a 77% diagnostic sensitivity (CI 71% to 82%), 85% specificity (CI 79% to 90%) and 87% positive predictive value (PPV) (CI 81% to 91%) were achieved. For pNfH, we calculated 83% sensitivity (CI 78% to 88%), 77% specificity (CI 71% to 83%) and 82% PPV (CI 77% to 86%) at 560 pg/mL. There were no significant differences between sporadic and genetic ALS or PLS. Nf levels were elevated at early disease stage, and correlated moderately with MND progression and duration.CONCLUSIONS: Neurofilaments in CSF have a high relevance for the differential diagnosis of MNDs and should be included in the diagnostic work-up of patients. Their value as prognostic markers should be investigated further.",
author = "Petra Steinacker and Emily Feneberg and Jochen Weishaupt and Johannes Brettschneider and Hayrettin Tumani and Andersen, {Peter M} and {von Arnim}, {Christine A F} and Sarah B{\"o}hm and Jan Kassubek and Christian Kubisch and Doroth{\'e}e Lul{\'e} and Hans-Peter M{\"u}ller and Rainer Muche and Elmar Pinkhardt and Patrick Oeckl and Angela Rosenbohm and Sarah Anderl-Straub and Volk, {Alexander E} and Patrick Weydt and Ludolph, {Albert C} and Markus Otto",
note = "Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/",
year = "2016",
month = jan,
doi = "10.1136/jnnp-2015-311387",
language = "English",
volume = "87",
pages = "12--20",
journal = "J NEUROL NEUROSUR PS",
issn = "0022-3050",
publisher = "BMJ PUBLISHING GROUP",
number = "1",

}

RIS

TY - JOUR

T1 - Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients

AU - Steinacker, Petra

AU - Feneberg, Emily

AU - Weishaupt, Jochen

AU - Brettschneider, Johannes

AU - Tumani, Hayrettin

AU - Andersen, Peter M

AU - von Arnim, Christine A F

AU - Böhm, Sarah

AU - Kassubek, Jan

AU - Kubisch, Christian

AU - Lulé, Dorothée

AU - Müller, Hans-Peter

AU - Muche, Rainer

AU - Pinkhardt, Elmar

AU - Oeckl, Patrick

AU - Rosenbohm, Angela

AU - Anderl-Straub, Sarah

AU - Volk, Alexander E

AU - Weydt, Patrick

AU - Ludolph, Albert C

AU - Otto, Markus

N1 - Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

PY - 2016/1

Y1 - 2016/1

N2 - OBJECTIVES: Biomarkers for the diagnosis of motoneuron diseases (MND) are urgently needed to improve the diagnostic pathway, patient stratification and monitoring. The aim of this study was to validate candidate markers for MND in cerebrospinal fluid (CSF) and specify cut-offs based on large patient cohorts by especially considering patients who were seen under the initial differential diagnosis (MND mimics).METHODS: In a prospective study, we investigated CSF of 455 patients for neurofilament light chain (NfL), phosphorylated heavy chain (pNfH), tau protein (Tau) and phospho-tau protein (pTau). Analysed cohorts included patients with apparently sporadic and familial amyotrophic lateral sclerosis (ALS) and primary lateral sclerosis (PLS) (MND, n=253), MND mimics (n=85) and neurological control groups. Cut-off values were specified, and diagnostic performance and correlation with progression were analysed.RESULTS: Nfs were significantly higher in the MND group compared to the control groups, whereas Tau and pTau did not differ. At a cut-off level of 2200 pg/mL for NfL, a 77% diagnostic sensitivity (CI 71% to 82%), 85% specificity (CI 79% to 90%) and 87% positive predictive value (PPV) (CI 81% to 91%) were achieved. For pNfH, we calculated 83% sensitivity (CI 78% to 88%), 77% specificity (CI 71% to 83%) and 82% PPV (CI 77% to 86%) at 560 pg/mL. There were no significant differences between sporadic and genetic ALS or PLS. Nf levels were elevated at early disease stage, and correlated moderately with MND progression and duration.CONCLUSIONS: Neurofilaments in CSF have a high relevance for the differential diagnosis of MNDs and should be included in the diagnostic work-up of patients. Their value as prognostic markers should be investigated further.

AB - OBJECTIVES: Biomarkers for the diagnosis of motoneuron diseases (MND) are urgently needed to improve the diagnostic pathway, patient stratification and monitoring. The aim of this study was to validate candidate markers for MND in cerebrospinal fluid (CSF) and specify cut-offs based on large patient cohorts by especially considering patients who were seen under the initial differential diagnosis (MND mimics).METHODS: In a prospective study, we investigated CSF of 455 patients for neurofilament light chain (NfL), phosphorylated heavy chain (pNfH), tau protein (Tau) and phospho-tau protein (pTau). Analysed cohorts included patients with apparently sporadic and familial amyotrophic lateral sclerosis (ALS) and primary lateral sclerosis (PLS) (MND, n=253), MND mimics (n=85) and neurological control groups. Cut-off values were specified, and diagnostic performance and correlation with progression were analysed.RESULTS: Nfs were significantly higher in the MND group compared to the control groups, whereas Tau and pTau did not differ. At a cut-off level of 2200 pg/mL for NfL, a 77% diagnostic sensitivity (CI 71% to 82%), 85% specificity (CI 79% to 90%) and 87% positive predictive value (PPV) (CI 81% to 91%) were achieved. For pNfH, we calculated 83% sensitivity (CI 78% to 88%), 77% specificity (CI 71% to 83%) and 82% PPV (CI 77% to 86%) at 560 pg/mL. There were no significant differences between sporadic and genetic ALS or PLS. Nf levels were elevated at early disease stage, and correlated moderately with MND progression and duration.CONCLUSIONS: Neurofilaments in CSF have a high relevance for the differential diagnosis of MNDs and should be included in the diagnostic work-up of patients. Their value as prognostic markers should be investigated further.

U2 - 10.1136/jnnp-2015-311387

DO - 10.1136/jnnp-2015-311387

M3 - SCORING: Journal article

C2 - 26296871

VL - 87

SP - 12

EP - 20

JO - J NEUROL NEUROSUR PS

JF - J NEUROL NEUROSUR PS

SN - 0022-3050

IS - 1

ER -